(NASDAQ:BIOA) STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA-B) partner Eisai announced today the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab subcutaneous injection for maintenance dosing....
Related Questions
How will the FDA approval of lecanemab subcutaneous injection affect BIOA's stock volatility and price targets in the short term?
What is the projected market share for BioArctic's lecanemab compared to existing Alzheimer’s therapies and upcoming pipeline candidates?
How might the approval impact BioArctic's revenue forecasts, partnership dynamics with Eisai, and potential reimbursement or pricing negotiations?